Table 3.

Ongoing trials investigating the combination therapy of ICIs

Checkpoint inhibitors	Phase	Patients (No.)	Clinical setting	Status	NCT numbers
Nivolumab + Ipilimumab	I/II	32	Child-Pugh A HCC	Recruiting	NCT03682276
Nivolumab + Ipilimumab	I	50	Unresectable HCC with Child Pugh Class A cirrhosis	Active, not recruiting	NCT03203304
Nivolumab + Ipilimumab	II	30	HCC with potential surgical resection	Active, not recruiting	NCT03222076
Nivolumab + Ipilimumab	III	650	Advanced HCC without prior systemic therapy	Recruiting	NCT04039607
Nivolumab + Ipilimumab	II	40	HCC with potential for curative surgical resection	Recruiting	NCT03510871
Nivolumab + Mogamulizumab	I	96	locally advanced or metastatic solid tumors	Completed	NCT02476123
Nivolumab + Relatlimab	I	20	Potentially resectable HCC	Not yet recruiting	NCT04658147
Pembrolizumab + Bavituximab	II	28	Locally advanced or metastatic HCC not amenable to locoregional therapy	Recruiting	NCT03519997
Durvalumab+ Tremelimumab	III	1504	Unresectable HCC without prior systemic therapy	Recruiting	NCT03298451
Durvalumab+ Tremelimumab	I	32	Unresectable, locally advanced liver cancer after radioembolization	Suspended	NCT04605731
Durvalumab+ Tremelimumab	II	433	Advanced HCC	Active, not recruiting	NCT02519348